RECOVER-NEURO:一项多中心,多臂,第二阶段,随机化,活跃比较试验的研究方案,评估SARS-CoV-2感染 (PASC) 后急性后果中认知功能障碍的三个干预措施
David S Knopman1, Daniel T Laskowitz2,3, Deborah C Koltai3
1Mayo Clinic, Rochester, MN, USA. knopman@mayo.edu.
Trials
|May 16, 2024
概括
这项研究调查了认知康复和脑刺激,以治疗COVID-19后的"脑雾". 结果可能会提供新的PASC认知恢复治疗方法.
科学领域:
- 神经学 神经学
- 认知科学 认知科学
- 传染病研究 传染病研究
背景情况:
- SARS-CoV-2 感染 (PASC) 后急性后果可能导致显著的认知功能障碍或"大脑雾".
- 这种认知障碍会影响记忆,注意力和集中力,影响日常功能和返回工作.
- 帕斯克症状影响着不同的人群,不管COVID-19的初始严重程度或人口因素如何.
研究的目的:
- 评估认知训练和大脑刺激对PASC相关认知功能障碍的有效性.
- 评估包括BrainHQ,PASC认知恢复和跨直流刺激 (tDCS) 在内的干预措施.
- 确定这些干预措施是否可以缓解"脑雾"症状,并改善PASC患者的认知功能.
主要方法:
- RECOVER-NEURO是一个前性的,多中心的,随机的,主动比较的第二阶段试验.
- 五个手臂将在10周内比较BrainHQ,PASC-认知恢复和tDCS干预措施.
- 认知测试和患者报告的调查将在基线和干预后进行.
主要成果:
- 研究结果正在等待.
- 该试验旨在确定新型PASC治疗的有效性.
- 数据分析将重点关注认知改善和患者报告的结果.
结论:
- 这项研究将测试PASC认知功能障碍的既定干预措施.
- 成功的结果可能会导致对"脑雾"和神经认知障碍的有益治疗.
- 这些发现可能为患有长期COVID认知障碍的人提供新的治疗选择.
更多相关视频
07:35Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System
Published on: December 29, 2023
1.2K
07:01Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
Published on: September 20, 2020
4.7K
相关概念视频
01:30Cognitive Development During Adulthood
94
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
94
01:22Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181